Group 1 - The core viewpoint of the news is that Kuaihua Pharmaceutical (002737.SZ) reported its Q3 2025 results, highlighting the institutional investor holdings and changes in share ownership [1] - As of October 27, 2025, six institutional investors hold a total of 301 million shares of Kuaihua Pharmaceutical, representing 51.53% of the total share capital [1] - The institutional holding ratio decreased by 0.86 percentage points compared to the previous quarter [1] Group 2 - Among public funds, two funds increased their holdings, namely E Fund CSI Dividend ETF and China Merchants CSI Dividend ETF, with a slight increase in holding ratio [1] - One public fund, Southern CSI 1000 ETF, reduced its holdings, resulting in a slight decrease in holding ratio [1] - A total of 81 public funds did not disclose their holdings this quarter, including notable funds such as Huaxia CSI 1000 ETF and GF CSI 1000 ETF [1] Group 3 - From the perspective of foreign investment, one foreign fund, Hong Kong Central Clearing Limited, reduced its holdings, leading to a slight decrease in holding ratio [2]

Core Viewpoint - Kew Flower Pharmaceutical announced the convening of its fifth board meeting to review the third quarter report for 2025, indicating ongoing corporate governance and financial oversight [1] Company Summary - Kew Flower Pharmaceutical's revenue composition for the first half of 2025 shows that the pharmaceutical industry accounts for 99.61% of its total revenue, while other businesses contribute only 0.39% [1] - As of the report, Kew Flower Pharmaceutical has a market capitalization of 9.1 billion yuan [1]

证券代码：002737 证券简称：葵花药业 公告编号：2025-068 葵花药业集团股份有限公司 关于 2022 年员工持股计划第三个锁定期届满的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 葵花药业集团股份有限公司（以下简称"公司"或"葵花药业"）于 2022 年 8 月 23 日召开第四届董事会第二十一次会议、第四届监事会第十四次会议， 于 2022 年 9 月 9 日召开 2022 年第二次临时股东大会，审议通过了《关于公司 2022 年员工持股计划（草案）及其摘要的议案》及相关议案，同意公司实施 2022 年员工持股计划，具体内容详见公司于 2022 年 8 月 24 日和 2022 年 9 月 10 日刊 登在巨潮资讯网上的相关公告。 根据《关于上市公司实施员工持股计划试点的指导意见》、《葵花药业集团 股份有限公司 2022 年员工持股计划（草案）》等相关规定，公司 2022 年员工持 股计划（以下简称"本次员工持股计划"）第三个锁定期现已届满，现将相关情 况公告如下： 第二批解锁时点：为自公司公告最后一笔标的股票过户至本次员工持股计划 ...

北京市天元律师事务所 关于葵花药业集团股份有限公司 2025 年第一次临时股东大会的法律意见 京天股字（2025）第 663 号 致：葵花药业集团股份有限公司 本所及经办律师同意将本法律意见作为本次股东大会公告的法定文件，随同其 他公告文件一并提交深圳证券交易所（以下简称"深交所"）予以审核公告，并依 法对出具的法律意见承担责任。 本所律师按照律师行业公认的业务标准、道德规范和勤勉尽责精神，对公司提 供的文件和有关事实进行了核查和验证，现出具法律意见如下： 一、 本次股东大会的召集、召开程序 公司第五届董事会于 2025 年 10 月 10 日召开第十一次会议，做出决议召集本 次股东大会，并及时通过指定信息披露媒体发出了《召开股东大会通知》。该《召 开股东大会通知》中载明了召开本次股东大会的时间、地点、审议事项、投票方式 和出席会议对象等内容。 本次股东大会采用现场投票和网络投票相结合的方式召开。本次股东大会现场 会议于 2025 年 10 月 27 日 13 时在黑龙江省哈尔滨市高新技术产业开发区迎宾路集 中区东湖路 18 号葵花药业集团股份有限公司一楼会议室召开，由董事长关玉秀女 士主持，完成了全部会议议 ...

2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决提案的情形。 证券代码：002737 证券简称：葵花药业 公告编号：2025-067 葵花药业集团股份有限公司 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议的召开情况 1、召开时间： （1）现场会议召开时间：2025 年 10 月 27 日（星期一）下午 13 时； （2）网络投票时间：2025 年 10 月 27 日，其中： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 10 月 27 日上午 9:15-9:25、9:30-11:30、13:00-15:00； 通过深圳证券交易所互联网投票系统进行网络投票的具体时间为：2025 年 10 月 27 日 9:15-15:00 期间的任意时间。 2、召开地点：葵花药业集团股份有限公司一楼会议室 3、召开方式：现场投票与网络投票 4、召集人：公司董事会 5、主持人：董事长关玉秀女士 6、会议通知于 2025 年 10 月 11 ...

葵花药业集团股份有限公司 证券代码：002737 证券简称：葵花药业 公告编号：2025-065 第五届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）第五届监事 会第六次会议于 2025 年 10 月 27 日上午 11 时以通讯方式召开，本次会议由监事 会主席何岩女士召集并主持。会议通知及议案于 2025 年 10 月 22 日通过电子邮 件形式发出。会议应出席监事三人，实际出席监事三人。 经审核，监事会认为董事会编制和审议葵花药业集团股份有限公司 2025 年 第三季度报告的程序符合法律、行政法规及中国证监会的规定，报告内容真实、 准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重 大遗漏。 表决结果：同意 3 票，反对 0 票，弃权 0 票，通过。 三、备查文件 1、公司第五届监事会第六次会议决议 特此公告。 葵花药业集团股份有限公司 监事会 2025 年 10 月 27 日 本次会议召集和召开程序符合《公司法》及《公司章程》的 ...

证券代码：002737 证券简称：葵花药业 公告编号：2025-064 葵花药业集团股份有限公司 第五届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 二、董事会会议审议情况 1、审议通过《关于公司 2025 年第三季度报告的议案》 表决结果：同意 9 票，反对 0 票，弃权 0 票，通过。 专门委员会审议情况:本议案提交董事会审议前业经公司第五届董事会审计 委员会 2025 年第四次会议审议通过。 三、备查文件: 1、公司第五届董事会第十二次会议决议 2、公司第五届董事会审计委员会 2025 年第四次会议决议 特此公告。 葵花药业集团股份有限公司 董 事 会 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）第五届董事 会第十二次会议于 2025 年 10 月 27 日上午 9 时以通讯方式召开。会议由公司董 事长关玉秀女士召集，会议通知及议案于 2025 年 10 月 22 日通过电子邮件形式 发出。会议应参加表决董事 9 人，实际参加表决董事 9 人。本次会议召集、召开 程序符合《公司法》及相关法 ...

Core Insights - The company reported a revenue of 374 million yuan for the third quarter, representing a year-on-year decline of 14.90% [1] - The net profit for the third quarter was a loss of 115 million yuan, a decrease of 214.27% compared to the previous year [1] - For the first three quarters, the total revenue was 1.684 billion yuan, down 43.24% year-on-year [1] - The net profit for the first three quarters showed a loss of 33.54 million yuan, reflecting a decline of 105.72% [1]

Revenue and Profitability - The company's revenue for Q3 2025 was ¥373,840,721.51, representing a decrease of 14.90% compared to the same period last year, and a year-to-date revenue of ¥1,683,984,047.39, down 43.24% year-on-year[5] - The net profit attributable to shareholders was -¥114,848,599.10 for the quarter, a decline of 214.27%, and a year-to-date net profit of -¥33,538,693.69, down 105.72%[5] - The basic and diluted earnings per share were both -¥0.20, reflecting a decrease of 217.65% compared to the same period last year[5] - The company experienced a substantial reduction in net profit for the quarter, which was -¥45,914,346.86, a decrease of 107.58% compared to the same period last year[10] - Total operating revenue for the current period was ¥1,683,984,047.39, a decrease of 43.3% compared to ¥2,966,906,461.88 in the previous period[17] - Net profit for the current period was a loss of ¥45,914,346.86, compared to a profit of ¥605,513,521.75 in the previous period, representing a significant decline[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,123,453,375.74, a decrease of 12.06% from the end of the previous year[5] - The company’s total equity attributable to shareholders decreased by 7.46% to ¥4,052,632,698.81 compared to the end of the previous year[5] - The company’s total current assets decreased from 3,885,593,091.44 yuan to 3,261,322,981.89 yuan, a decline of approximately 16%[13] - Total current liabilities decreased from 1,027,526,250.87 yuan to 720,514,381.01 yuan, a decline of approximately 30%[14] - The total liabilities decreased to ¥891,554,090.46 from ¥1,235,876,758.46, reflecting a reduction of 28%[15] Cash Flow and Investments - The cash flow from operating activities for the year-to-date was ¥220,323,992.20, an increase of 155.20% compared to the same period last year[10] - The net cash flow from operating activities was ¥220,323,992.20, a recovery from a negative cash flow of ¥399,173,131.02 in the previous period[20] - Cash inflows from operating activities totaled ¥1,686,942,207.77, down 35.4% from ¥2,610,224,347.59 in the previous period[20] - Investment cash inflows were significantly higher at ¥8,119,116,312.91 compared to ¥3,400,000,000.00 in the previous period, indicating a strong investment recovery[20] - Net cash flow from investment activities was -276,914,999.75, compared to 254,800,846.26 in the previous period, indicating a decline in investment performance[21] - Total cash inflow from financing activities was 18,000,000.00, while cash outflow was 314,007,935.81, resulting in a net cash flow from financing activities of -296,007,935.81[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 52,430[11] - The largest shareholder, KuaHua Group Co., Ltd., holds 45.41% of shares, totaling 265,200,000 shares[11] Operational Efficiency - The company reported a significant decrease in sales expenses, which amounted to ¥336,479,049.08, down 37.70% year-on-year, attributed to reduced sales and enhanced cost control[9] - The investment income increased by 53.89% to ¥19,675,919.34, primarily due to higher returns from financial products[9] - The company reported a significant reduction in employee compensation liabilities from 165,286,636.67 yuan to 67,586,943.36 yuan, a decrease of about 59%[14] Financial Reporting and Standards - The company did not undergo an audit for the third quarter financial report, which may affect investor confidence[22] - The company plans to implement new accounting standards starting in 2025, which may impact future financial reporting[22]

Core Insights - On October 22, Kewang Pharmaceutical's stock rose by 1.17%, with a trading volume of 798.94 million yuan [1] - As of September 30, the number of shareholders decreased by 2.06% to 52,400, while the average circulating shares per person increased by 2.10% to 11,145 shares [2] Financing and Margin Trading - On October 22, Kewang Pharmaceutical had a financing buy amount of 6.15 million yuan and a financing repayment of 13.38 million yuan, resulting in a net financing buy of -7.24 million yuan [1] - The total margin trading balance as of October 22 was 157 million yuan, with the financing balance at 155 million yuan, accounting for 1.70% of the circulating market value, which is below the 10th percentile level over the past year [1] - The company had a short selling repayment of 800 shares and a short selling amount of 900 shares on October 22, with a short selling balance of 127.93 million yuan, also below the 10th percentile level over the past year [1] Financial Performance - For the first half of 2025, Kewang Pharmaceutical reported a revenue of 1.31 billion yuan, a year-on-year decrease of 48.17%, and a net profit attributable to shareholders of 81.31 million yuan, down 83.28% year-on-year [2] - Cumulatively, the company has distributed 4.045 billion yuan in dividends since its A-share listing, with 1.752 billion yuan distributed over the past three years [3] Shareholder Structure - As of June 30, 2025, the top ten circulating shareholders included E Fund CSI Dividend ETF, which held 3.1612 million shares, a decrease of 436,800 shares from the previous period [3] - Hong Kong Central Clearing Limited entered as a new shareholder, holding 2.9699 million shares, while Southern CSI 1000 ETF also entered as a new shareholder with 2.6960 million shares [3]